Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3429 participants.

Also called NCT02193971

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,429 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02193971
Other papers using this trial's data
  • Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: The HOST-REDUCE-POLYTECH-ACS Trial Circulation, 2021-03-16 DOI, PubMed 33205662
  • Durable-polymer versus biodegradable-polymer drug-eluting stents in acute coronary syndromes: three-year outcomes of the HOST REDUCE POLYTECH RCT Trial EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2024-06-17 DOI, PubMed 38887886, PMC11163442 Not in the PMC Open Access subset.
  • Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial JAMA cardiology, 2022-04-01 DOI, PubMed 35262625, PMC8908232 Not in the PMC Open Access subset.
  • Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial European heart journal. Cardiovascular pharmacotherapy, 2023-04-10 DOI, PubMed 36715152

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02193971. Randomized; no masking; primary purpose treatment. Start 2014-07 (actual); primary completion 2020-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)
Condition
Acute Coronary Syndrome
Intervention (Device)
BS-DES (Biostable polymer drug-eluting stent)
Intervention (Device)
BD-DES (Biodegradable polymer drug-eluting stent)
Intervention (Drug)
Prasugrel 5mg
Lead sponsor
Seoul National University Hospital (class: other)
Collaborator
Boston Scientific Korea Co. Ltd (class: industry)
Collaborator
Dio (class: industry)
Collaborator
Terumo Corporation (class: industry)
Collaborator
Abbott (class: industry)

Record details

Record id
cardio:ct-nct02193971
Content hash
b6e4c4d39e17822a6df11af46108cf73e3cdeb2905c85ab1f2d42ef8bd106ad6